{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:06:45Z","timestamp":1761512805367},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":2010,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1097\/jto.0b013e3181d86a4f","type":"journal-article","created":{"date-parts":[[2010,4,27]],"date-time":"2010-04-27T17:09:40Z","timestamp":1272388180000},"page":"862-866","source":"Crossref","is-referenced-by-count":5,"title":["A Phase II Trial of Carboplatin and Weekly Topotecan in the First-Line Treatment of Patients with Extensive Stage Small Cell Lung Cancer"],"prefix":"10.1016","volume":"5","author":[{"given":"David R.","family":"Spigel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Hainsworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jitendra G.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor G.","family":"Gian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James D.","family":"Peyton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"West-Osterfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bobby L.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth R.","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne F.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Howard A.","family":"Burris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. Anthony","family":"Greco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e3181d86a4f_bib1","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.2005.04.8595","article-title":"Randomized phase III trial comparing irinotecan\/cisplatin with etoposide\/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer","volume":"24","author":"Hanna","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181d86a4f_bib2","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2007.15.7545","article-title":"Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial","volume":"26","author":"Hermes","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"10.1097\/JTO.0b013e3181d86a4f_bib3","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1200\/jco.2008.26.15_suppl.7512","article-title":"S0124: a randomized phase III trial comparing irinotecan\/cisplatin (IP) with etoposide\/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC)","volume":"26","author":"Natale","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181d86a4f_bib4","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/annonc\/mdj137","article-title":"A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer","volume":"17","author":"Schmittel","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0b013e3181d86a4f_bib5","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.1999.17.2.658","article-title":"Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer","volume":"17","author":"von Pawel","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181d86a4f_bib6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00280-005-0034-3","article-title":"Combination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a phase II study of the hellenic cooperative oncology group (HeCOG)","volume":"57","author":"Christodoulou","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1097\/JTO.0b013e3181d86a4f_bib7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/annonc\/mdl353","article-title":"Randomised phase II study comparing topotecan\/carboplatin administration for 5 versus 3 days in the treatment of extensive-stage small-cell lung cancer","volume":"18","author":"Seifart","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0b013e3181d86a4f_bib8","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JTO.0b013e31817e0f58","article-title":"Phase II study of a 3-day schedule with topotecan and cisplatin in patients with previously untreated small cell lung cancer and extensive disease","volume":"3","author":"Sorensen","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e3181d86a4f_bib9","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2005.03.3332","article-title":"Open-label, multicenter, randomized, phase III study comparing oral topotecan\/cisplatin versus etoposide\/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer","volume":"24","author":"Eckardt","year":"2006","journal-title":"J Clin Oncol"},{"issue":"Suppl 6","key":"10.1097\/JTO.0b013e3181d86a4f_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1634\/theoncologist.9-90006-25","article-title":"Emerging role of weekly topotecan in recurrent small cell lung cancer","volume":"9","author":"Eckardt","year":"2004","journal-title":"Oncologist"},{"key":"10.1097\/JTO.0b013e3181d86a4f_bib11","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1634\/theoncologist.7-4-324","article-title":"Weekly topotecan: an alternative to topotecan's standard daily \u00d7 5 schedule?","volume":"7","author":"Rowinsky","year":"2002","journal-title":"Oncologist"},{"key":"10.1097\/JTO.0b013e3181d86a4f_bib12","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ygyno.2004.08.026","article-title":"Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer","volume":"95","author":"Bhoola","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1097\/JTO.0b013e3181d86a4f_bib13","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1006\/gyno.2001.6435","article-title":"A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients","volume":"83","author":"Homesley","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1097\/JTO.0b013e3181d86a4f_bib14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000127384","article-title":"Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy","volume":"73","author":"Largillier","year":"2007","journal-title":"Oncology"},{"issue":"3 Pt 2","key":"10.1097\/JTO.0b013e3181d86a4f_bib15","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0090-8258(03)00470-0","article-title":"Weekly topotecan in the management of ovarian cancer","volume":"90","author":"Morris","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1097\/JTO.0b013e3181d86a4f_bib16","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ygyno.2004.07.035","article-title":"Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature","volume":"95","author":"Traina","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"Suppl 18","key":"10.1097\/JTO.0b013e3181d86a4f_bib17","doi-asserted-by":"crossref","first-page":"17000","DOI":"10.1200\/jco.2006.24.18_suppl.17000","article-title":"Topotecan\u2014single agent activity in a weekly intravenous (IV) schedule for first-line therapy in poor prognosis extensive stage small cell lung cancer (SCLC): a Minnie Pearl Cancer Research Network phase II trial","volume":"24","author":"Murphy","year":"2006","journal-title":"J Clin Oncol"},{"issue":"Suppl 18","key":"10.1097\/JTO.0b013e3181d86a4f_bib18","doi-asserted-by":"crossref","first-page":"7083","DOI":"10.1200\/jco.2006.24.18_suppl.7083","article-title":"Topotecan: weekly intravenous (IV) schedule similar to standard 5-day IV schedule as second-line therapy for relapsed small cell lung cancer (SCLC): a Minnie Pearl Cancer Research Network phase II trial","volume":"24","author":"Shipley","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181d86a4f_bib19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/JTO.0b013e3181d86a4f_bib20","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181d86a4f_bib21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1097\/JTO.0b013e3181d86a4f_bib22","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.ygyno.2005.07.020","article-title":"A phase I\/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma","volume":"99","author":"Rose","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"Suppl 15","key":"10.1097\/JTO.0b013e3181d86a4f_bib23","doi-asserted-by":"crossref","first-page":"16518","DOI":"10.1200\/jco.2008.26.15_suppl.16518","article-title":"An open-label, single arm, phase II study of IV weekly (days 1 and 8) topotecan in combination with carboplatin (day 1) every 21 days as second-line therapy in subjects with platinum-sensitive relapsed ovarian cancer: first stage results","volume":"26","author":"Schwartz","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl 14","key":"10.1097\/JTO.0b013e3181d86a4f_bib24","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1200\/jco.2004.22.14_suppl.5147","article-title":"A phase I trial of weekly topotecan and carboplatin in potentially platinum sensitive ovarian and peritoneal carcinoma","volume":"22","author":"Smrekar","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181d86a4f_bib25","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.lungcan.2007.02.014","article-title":"A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer","volume":"57","author":"Shah","year":"2007","journal-title":"Lung Cancer"},{"issue":"Suppl 15","key":"10.1097\/JTO.0b013e3181d86a4f_bib26","doi-asserted-by":"crossref","first-page":"19073","DOI":"10.1200\/jco.2008.26.15_suppl.19073","article-title":"Phase II trial of high-dose weekly topotecan in patients with relapsed small-cell lung cancer (SCLC)","volume":"26","author":"Shipley","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415305165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415305165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T02:05:45Z","timestamp":1591236345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415305165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S1556086415305165"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e3181d86a4f","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}